With the onset of the COVID-19 crisis in March, we decided to include April data in our first 2020 report to better illustrate any early indicators of effects of the pandemic on the financing environment. Additionally, we have broken out specific statistics by month and industry (technology/life sciences/other) to offer more targeted insights. During the first four months of 2020, Cooley handled 465 disclosable deals representing more than $13.4 billion of invested capital. Median pre-money valuations remained relatively strong across deal stages, though valuations did decrease in Series C transactions. In a possible preview of future quarters, the percentage of down rounds increased to 16% of transactions during April, a level not seen since Q4 2016. Deal terms during the four month period were mixed. The percentage of deals using full participating liquidation preferences decreased to 7.4% of transactions in April, compared to 7.6% of transactions from January to March. However, there was a slight increase in the percentage of deals involving recapitalizations compared to prior quarters. This will be a data point to monitor in the coming months.